ECSP088884A - Compuestos heterociclicos fusionados y su uso como moduladores de mglur5 - Google Patents
Compuestos heterociclicos fusionados y su uso como moduladores de mglur5Info
- Publication number
- ECSP088884A ECSP088884A EC2008008884A ECSP088884A ECSP088884A EC SP088884 A ECSP088884 A EC SP088884A EC 2008008884 A EC2008008884 A EC 2008008884A EC SP088884 A ECSP088884 A EC SP088884A EC SP088884 A ECSP088884 A EC SP088884A
- Authority
- EC
- Ecuador
- Prior art keywords
- fusioned
- mglur5
- modulators
- compounds
- heterociclical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención está dirigida a nuevos compuestos, aun proceso para su preparación y su uso en terapia y las composiciones farmacéuticas que comprenden los nuevos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79766306P | 2006-05-05 | 2006-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088884A true ECSP088884A (es) | 2008-12-30 |
Family
ID=38668441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008884A ECSP088884A (es) | 2006-05-05 | 2008-11-12 | Compuestos heterociclicos fusionados y su uso como moduladores de mglur5 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070259860A1 (es) |
| EP (1) | EP2027129A2 (es) |
| JP (1) | JP2009536213A (es) |
| KR (1) | KR20090018935A (es) |
| CN (1) | CN101484455A (es) |
| AR (1) | AR060811A1 (es) |
| AU (1) | AU2007248292A1 (es) |
| BR (1) | BRPI0710980A2 (es) |
| CA (1) | CA2650255A1 (es) |
| CL (1) | CL2007001178A1 (es) |
| EC (1) | ECSP088884A (es) |
| IL (1) | IL194815A0 (es) |
| MX (1) | MX2008013834A (es) |
| NO (1) | NO20084852L (es) |
| RU (1) | RU2008141511A (es) |
| TW (1) | TW200808800A (es) |
| UY (1) | UY30308A1 (es) |
| WO (1) | WO2007130824A2 (es) |
| ZA (1) | ZA200809019B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
| WO2009054794A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amino 1,2,4-triazole derivatives as modulators of mglur5 |
| WO2009054787A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5 |
| TW200922586A (en) * | 2007-10-26 | 2009-06-01 | Astrazeneca Ab | Thiophene 1,2,4-triazole derivatives as modulators of mGluR5 |
| WO2009054785A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole ether derivatives as modulators of mglur5 |
| WO2009054790A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
| WO2009054791A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5 |
| WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
| KR20110101164A (ko) * | 2008-12-18 | 2011-09-15 | 아스트라제네카 아베 | 1-〔5-(3-클로로-페닐)-이소옥사졸-3-일〕-에타논 및 (r)-1-〔5-(3-클로로-페닐)-이속사졸-3-일〕-에탄올의 신규 제조 방법 |
| JP5620129B2 (ja) * | 2009-03-19 | 2014-11-05 | 富士フイルム株式会社 | 光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物 |
| WO2011007756A1 (ja) | 2009-07-13 | 2011-01-20 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| WO2011082010A1 (en) | 2009-12-29 | 2011-07-07 | Eli Lilly And Company | Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia |
| WO2012029991A1 (en) | 2010-09-02 | 2012-03-08 | Takeda Pharmaceutical Company Limited | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment |
| PE20151979A1 (es) | 2013-01-23 | 2016-01-15 | Astrazeneca Ab | Compuestos quimicos |
| EP2857387A1 (en) | 2013-10-07 | 2015-04-08 | Boehringer Ingelheim International Gmbh | Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid |
| TWI891782B (zh) | 2020-05-06 | 2025-08-01 | 德商拜耳廠股份有限公司 | 作為殺蟲劑之新穎雜芳基三唑化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000056315A1 (en) * | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Treatment of pain |
| US7074809B2 (en) * | 2002-08-09 | 2006-07-11 | Astrazeneca Ab | Compounds |
| TW200812986A (en) * | 2002-08-09 | 2008-03-16 | Nps Pharma Inc | New compounds |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| BRPI0507495A (pt) * | 2004-02-18 | 2007-07-10 | Astrazeneca Ab | composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5 |
| JP5084269B2 (ja) * | 2004-02-18 | 2012-11-28 | アストラゼネカ アクチボラグ | テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用 |
-
2007
- 2007-04-24 TW TW096114393A patent/TW200808800A/zh unknown
- 2007-04-25 WO PCT/US2007/067371 patent/WO2007130824A2/en not_active Ceased
- 2007-04-25 EP EP07811855A patent/EP2027129A2/en not_active Withdrawn
- 2007-04-25 MX MX2008013834A patent/MX2008013834A/es not_active Application Discontinuation
- 2007-04-25 US US11/790,429 patent/US20070259860A1/en not_active Abandoned
- 2007-04-25 CA CA002650255A patent/CA2650255A1/en not_active Abandoned
- 2007-04-25 CN CNA2007800254542A patent/CN101484455A/zh active Pending
- 2007-04-25 CL CL2007001178A patent/CL2007001178A1/es unknown
- 2007-04-25 BR BRPI0710980-6A patent/BRPI0710980A2/pt not_active IP Right Cessation
- 2007-04-25 UY UY30308A patent/UY30308A1/es not_active Application Discontinuation
- 2007-04-25 JP JP2009509957A patent/JP2009536213A/ja active Pending
- 2007-04-25 AR ARP070101784A patent/AR060811A1/es unknown
- 2007-04-25 AU AU2007248292A patent/AU2007248292A1/en not_active Abandoned
- 2007-04-25 KR KR1020087029721A patent/KR20090018935A/ko not_active Withdrawn
- 2007-04-25 RU RU2008141511/04A patent/RU2008141511A/ru not_active Application Discontinuation
-
2008
- 2008-10-21 ZA ZA200809019A patent/ZA200809019B/xx unknown
- 2008-10-22 IL IL194815A patent/IL194815A0/en unknown
- 2008-11-12 EC EC2008008884A patent/ECSP088884A/es unknown
- 2008-11-18 NO NO20084852A patent/NO20084852L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007001178A1 (es) | 2008-01-18 |
| KR20090018935A (ko) | 2009-02-24 |
| WO2007130824A3 (en) | 2008-05-22 |
| US20070259860A1 (en) | 2007-11-08 |
| AU2007248292A1 (en) | 2007-11-15 |
| UY30308A1 (es) | 2007-11-30 |
| IL194815A0 (en) | 2009-08-03 |
| ZA200809019B (en) | 2009-08-26 |
| JP2009536213A (ja) | 2009-10-08 |
| EP2027129A2 (en) | 2009-02-25 |
| BRPI0710980A2 (pt) | 2011-05-31 |
| RU2008141511A (ru) | 2010-06-20 |
| NO20084852L (no) | 2009-01-14 |
| AR060811A1 (es) | 2008-07-16 |
| TW200808800A (en) | 2008-02-16 |
| WO2007130824A2 (en) | 2007-11-15 |
| MX2008013834A (es) | 2008-11-10 |
| AU2007248292A8 (en) | 2008-12-04 |
| CA2650255A1 (en) | 2007-11-15 |
| CN101484455A (zh) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088884A (es) | Compuestos heterociclicos fusionados y su uso como moduladores de mglur5 | |
| ECSP10010015A (es) | Inhibidores de proteasoma | |
| UY31806A (es) | Compuestos de tiazole y oxazole de sulfonamida de benceno | |
| CL2008002319A1 (es) | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
| CR11623A (es) | Compuestos | |
| GT201000023A (es) | Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met. | |
| CR20160475A (es) | Derivados de ácido 1-amino-2-ciclobutiletilborónico | |
| CL2008001815A1 (es) | Compuestos derivados de indazol; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar cancer. | |
| CR20160014A (es) | Compuestos de éster boronato y composiciones farmacéuticas de los mismos | |
| CR10149A (es) | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico | |
| CL2008001835A1 (es) | Uso de compuestos derivados de guaninas policiclicas para tratar la inflamacion; compuestos derivados de guanina; y compocicion farmaceutica que los comprende. | |
| UY30610A1 (es) | Moduladores de mglur5 | |
| CL2009001484A1 (es) | Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia. | |
| UY30304A1 (es) | Moduladores de mglur5 i | |
| UY30195A1 (es) | Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones | |
| ECSP088288A (es) | DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2 | |
| UY30808A1 (es) | Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones | |
| UY31990A (es) | Nuevos derivados | |
| UY30215A1 (es) | Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones | |
| HN2008000088A (es) | Heterociclicos de 1,4-dihidropiridina- fusionada, procesos para preparar los mismos, su uso y las composiciones que los contienen. | |
| UY30307A1 (es) | Moduladores de mglur5 vi | |
| UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| UY30305A1 (es) | Moduladores de mglur5 iv | |
| CL2007003223A1 (es) | Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades. | |
| CR11391A (es) | Derivados 1,2,4-triazol amino como moduladores de mglur5 |